Masking and triggered unmasking of targeting ligands on liposomal chemotherapy selectively suppress tumor growth in vivo

Molecular Pharmaceutics

Volumn 10, Issue 1, 2013, Pages 152-160

  Bandekar, Amey ^a   Zhu, Charles ^a   Gomez, Ana ^a   Menzenski, Monica Zofia ^b   Sempkowski, Michelle ^c   Sofou, Stavroula ^a  

^a RUTGERS UNIVERSITY   (United States)

^b NEW YORK UNIVERSITY   (United States)

^c The College of New Jersey   (United States)

Author keywords

anti HER2 liposomal doxorubicin; liposomal doxorubicin; masking unmasking targeting functionality; pH tunable liposomes

Indexed keywords

DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; LIGAND; LIPOSOME;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BINDING AFFINITY; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER CONTROL; CANCER GROWTH; CELLULAR PARAMETERS; CONTROLLED STUDY; DRUG BINDING; DRUG EFFICACY; DRUG EXTRAVASATION; ENDOSOME; FEASIBILITY STUDY; FEMALE; GENE OVEREXPRESSION; IN VIVO STUDY; INTERNALIZATION; INTERSTITIUM; LIPID VESICLE; MONOLAYER CULTURE; MOUSE; NONHUMAN; PH; PRIORITY JOURNAL; TUMOR XENOGRAFT; VASCULARIZATION; VESICLE BURST RELEASE; ZETA POTENTIAL;

ANIMALS; ANTIBIOTICS, ANTINEOPLASTIC; BREAST NEOPLASMS; CELL GROWTH PROCESSES; CELL LINE, TUMOR; DOXORUBICIN; DRUG DELIVERY SYSTEMS; ENDOSOMES; FEMALE; HUMANS; HYDROGEN-ION CONCENTRATION; LIGANDS; LIPIDS; LIPOSOMES; MICE; MICE, INBRED BALB C; MICE, NUDE; PERMEABILITY; RECEPTOR, ERBB-2; TUMOR BURDEN;

EID: 84872156261     PISSN: 15438384     EISSN: 15438392     Source Type: Journal    
DOI: 10.1021/mp3002717     Document Type: Article

References (52)

1. Howlader, N.; Krapcho, M.; Neyman, N.; Aminou, R.; Waldron, W.; Altekruse, S. F.; Kosary, C. L.; Ruhl, J.; Tatalovich, Z.; Cho, H.; Mariotto, A.; Eisner, M. P.; Lewis, D. R.; Chen, H. S.; Feuer, E. J.; Cronin, K. A.; Edwards, B. K. SEER Cancer Statistics Review, 1975-2008; National Cancer Institute: Bethesda, MD, 2011.
2. Sawant, R. R.; Torchilin, V. P. Challenges in development of targeted liposomal therapeutics AAPS 2012, 33, 303-315
3. Li, S.-D.; Huang, L. Pharmacokinetics and Biodistribution of Nanoparticles Mol. Pharmaceutics 2008, 5, 496-504
4. Sofou, S. Surface-active liposomes for targeted cancer therapy Nanomedicine 2007, 2, 711-724
5. Karve, S.; Bandekar, A.; Ali, M. R.; Sofou, S. The pH-dependent association with cancer cells of tunable functionalized lipid vesicles with encapsulated doxorubicin for high cell-kill selectivity Biomaterials 2010, 31, 4409-4416
6. McNeeley, K. M.; Karathanasis, E.; Annapragada, A. V.; Bellamkonda, R. V. Masking and triggered unmasking of targeting ligands on nanocarriers to improve drug delivery to brain tumors Biomaterials 2009, 30, 3986-3995
7. Rui, K.; Wenmin, Y.; Wanyu, L.; Qin, Y.; Tang, J.; Yuan, M.; Fu, L.; Ran, R.; Zhang, Z.; He, Q. Targeted Delivery of Cargoes into a Murine Solid Tumor by a Cell-Penetrating Peptide and Cleavable Poly(ethylene glycol) Comodified Liposomal Delivery System via Systemic Administration Mol. Pharmaceutics 2011, 8, 2151-2161
8. Sawant, R. M.; Hurley, J. P.; Salmaso, S.; Kale, A.; Tolcheva, E.; Levchenko, T. S.; Torchilin, V. P. "SMART" Drug Delivery Systems: Double-Targeted pH-Responsive Pharmaceutical Nanocarriers Bioconjugate Chem. 2006, 17, 943-949
9. Press, M. F.; Cordon-Cardo, C.; Slamon, D. J. Expression of the HER-2/neu proto-oncogene in normal human adult and fetal tissues Oncogene 1990, 5, 953-962
10. Allen, T. M. Ligand-targeted therapeutics in anticancer therapy Nat. Cancer Rev. 2002, 2, 750-763
11. Kirpotin, D. B.; Drummond, D. C.; Shao, Y.; Shalaby, M. R.; Hong, K.; Nielsen, U. B.; Marks, J. D.; Benz, C. C.; Park, J. W. Antibody Targeting of Long-Circulating Lipidic Nanoparticles Does Not Increase Tumor Localization but Does Increase Internalization in Animal Models Cancer Res. 2006, 66, 6732-6740
12. Park, J. W.; Hong, K.; Kirpotin, D. B.; Colbern, G.; Shalaby, R.; Baselga, J.; Shao, Y.; Nielsen, U. B.; Marks, J. D.; Moore, D.; Papahadjopoulos, D.; Benz, C. C. Anti-HER2 Immunoliposomes: Enhanced Efficacy Attributable to Targeted Delivery Clin. Cancer Res. 2002, 8, 1172-1181
13. Kirchmeier, M. J.; Ishida, T.; Chevrette, J.; Allen, T. M. Correlations between the rate of intracellular release of endocytosed liposomal doxorubicin and cytotoxicity as determined by a new assay J. Lipid Res. 2001, 11, 15-29
14. Yatvin, M. B.; Kreutz, W.; Horwitz, B. A.; Shinitzky, M. pH-sensitive liposomes: possible clinical implications Science 1980, 210, 1253-1255
15. Simoes, S.; Moreira, J. N.; Fonseca, C.; Düzgünes, N.; Pedroso de Lima, M. On the formulation of pH-sensitive liposomes with long circulation times Adv. Drug Delivery Rev. 2004, 56, 947-965
16. Slepushkin, V. A.; Simoes, S.; Dazin, P.; Newman, M. S.; Guo, L. S.; Pedroso de Lima, M.; Düzgünes, N. Sterically stabilized pH-sensitive liposomes J. Biol. Chem. 1997, 272, 2382-2388
17. Bajagur Kempegowda, G.; Karve, S.; Bandekar, A.; Adhikari, A.; Khaimchayev, T.; Sofou, S. pH-dependent formation of lipid heterogeneities controls surface topography and binding reactivity in functionalized bilayers Langmuir 2009, 25, 8144-8151
18. Helmlinger, G.; Yuan, F.; Dellian, M.; Jain, R. K. Interstitial pH and pO2 gradients in solid tumors in vivo: high-resolution measurements reveal a lack of correlation Nat. Med. 1997, 3, 177-182
19. Vaupel, P.; Kallinowski, F.; Okunieff, P. Blood Flow, Oxygen and Nutrient Supply, and Metabolic Microenvironment of Human Tumors: A Review Cancer Res. 1989, 49, 6449-6465
20. Mellman, I. The importance of being acid: the role of acidification in intracellular membrane traffic J. Exp. Biol. 1992, 172, 39-45
21. Tai, W.; Mahato, R.; Cheng, K. The role of HER2 in cancer therapy and targeted drug delivery J. Controlled Release 2010, 146, 264-275
22. Carey, L. A.; Perou, C. M.; Livasy, C. A.; Dressler, L. G.; Cowan, D.; Conway, K.; Karaca, G.; Troester, M. A.; Tse, C. K.; Edmiston, S.; Deming, S. L.; Geradts, J.; Cheang, M. C. U.; Nielsen, T. O.; Moorman, P. G.; Earp, H. S.; Millikan, R. C. Race, Breast Cancer Subtypes, and Survival in the Carolina Breast Cancer Study JAMA: J. Am. Med. Assoc. 2006, 295, 2492-2502
23. Muss, H. B.; Thor, A. D.; Berry, D. A.; Kute, T.; Liu, E. T.; Koerner, F.; Cirrincione, C. T.; Budman, D. R.; Wood, W. C.; Barcos, M.; Henderson, I. c-erbB-2 expression and response to adjuvant chemotherapy in women with node-positive early breast cancer N. Engl. J. Med. 1994, 330, 1260-1266
24. Ravdin, P. M. Should HER2 status be routinely measured for all breast cancer patients? Semin. Oncol. 1999, 26, 117-123
25. Kumar, S. R.; Quinn, T. P.; Deutscher, S. L. Evaluation of an 111In-Radiolabeled Peptide as a Targeting and Imaging Agent for ErbB-2 Receptor-Expressing Breast Carcinomas Clin. Cancer Res. 2007, 13, 6070-6079
26. Haran, G.; Cohen, R.; Bar, L. K.; Barenholz, Y. Transmembrane ammonium sulfate gradients in liposomes produce efficient and stable entrapment of amphipathic weak bases Biochim. Biophys. Acta 1993, 1151, 201-215
27. Euhus, D. M.; Hudd, C.; LaRegina, M. C.; Johnson, F. E. Tumor measurement in nude mouse J. Surg. Oncol. 1986, 31, 229-234
28. Tomayko, M. M.; Reynolds, C. P. Determination of subcutaneous tumor size in athymic (nude) mice Cancer Chemother. Pharmacol. 1989, 24, 148-154
29. Bandekar, A.; Karve, S.; M.-Y., C.; Mu, Q.; Rotolo, J.; Sofou, S. Antitumor efficacy following the intracellular and interstitial release of liposomal doxorubicin Biomaterials 2012, 33, 4345-4352
30. Karve, S.; Alaouie, A.; Zhou, Y.; Rotolo, J.; Sofou, S. The use of pH-triggered leaky heterogeneities on rigid lipid bilayers to improve intracellular trafficking and therapeutic potential of targeted liposomal immunochemotherapy Biomaterials 2009, 30, 6055-6064
31. Born, R.; Eicholtz-Wirth, H. Effect of different physiological conditions on the actions of Adriamycin on Chinese hamster cells in vitro Br. J. Cancer 1981, 44, 241-246
32. Drummond, D. D.; Meyer, O.; Hong, K.; Kirpotin, D. B.; Papahadjopoulos, D. Optimizing liposomes for delivery of chemotherapeutic agents to solid tumors Pharmacol. Rev. 1999, 51, 691-743
33. Park, J. W.; Benz, C. C.; Martin, F. J. Future directions of liposome- and immunoliposome-based cancer therapeutics Semin. Oncol. 2004, 31, 196-205
34. Park, J. Liposome-based drug delivery in breast cancer treatment Breast Cancer Res. 2002, 4, 95-99
35. deFazio, A.; Chiew, Y. E.; Sini, R. L.; Janes, P. W.; Sutherland, R. L. Expression of c- erb B receptors, heregulin and oestrogen receptor in human breast cell lines Int. J. Cancer 2000, 87, 487-498
36. Bandekar, A.; Sofou, S. Floret-shaped solid domains on giant fluid lipid vesicles induced by pH Langmuir 2012, 28, 4113-4122
37. Tokutomi, S.; Ohki, K.; Ohnishi, S. I. Proton-induced phase separation in phosphatidylserine/phosphatidylcholine membranes Biochim. Biophys. Acta 1980, 596, 192-200
38. de Gennes, P. G. Conformations of polymers attached to an interface Macromolecules 1980, 13, 1069-1075
39. Fadok, V. A.; Voelker, D. R.; Campbell, P. A.; Cohen, J. J.; Bratton, D. L.; Henson, P. M. Exposure of phosphatidylserine on the surface of apoptotic lymphocytes triggers specific recognition and removal by macrophages J. Immunol. 1992, 148, 2207-2216
40. Levchenko, T. S.; Rammohan, R.; Lukyanov, A. N.; Whiteman, K. R.; Torchilin, V. P. Liposome clearance in mice: the effect of a separate and combined presence of surface charge and polymer coating Int. J. Pharm. 2002, 240, 95-102
41. Liu, F.; Liu, D. Serum independent liposome uptake by mouse liver Biochim. Biophys. Acta 1996, 1278, 5-11
42. Lee, K.-D.; Hong, K.; Papahadjopoulos, D. Recognition of liposomes by cells: In vitro binding and endocytosis mediated by specific lipid headgroups and surface charge density Biochim. Biophys. Acta. Biomembr. 1992, 1103, 185-197
43. Mannello, F.; Qin, W.; Zhu, W.; Fabbri, L.; Tonti, G.; Sauter, E. Nipple aspirate fluids from women with breast cancer contain increased levels of group IIa secretory phospholipase A2 Breast Cancer Res. Treat. 2008, 111, 209-218
44. Davidsen, J.; Vermehren, C.; Frokjaer, S.; Mouritsen, O. G.; Jorgensen, K. Drug delivery by phospholipase A2 degradable liposomes Int. J. Pharm. 2001, 214, 67-69
45. Gabizon, A.; Papahadjopoulos, D. Liposome formulations with prolonged circulation time in blood and enhanced uptake by tumors Proc. Natl. Acad. Sci. U.S.A. 1988, 85, 6949-6953
46. Kenworthy, A. K.; Simon, S. A.; McIntosh, T. J. Structure and phase behavior of lipid suspensions containing phospholipids with covalently attached poly(ethylene glycol) Biophys. J. 1995, 68, 1903-1920
47. Yuan, F.; Leunig, M.; Huang, S. K.; Berk, D. A.; Papahadjopoulos, D.; Jain, R. K. Microvascular permeability and interstitial penetration of sterically stabilized (stealth) liposomes in a human tumor xenograft Cancer Res. 1994, 54, 3352-3356
48. Thurber, G. M.; Schmidt, M. M.; Wittrup, K. D. Antibody tumor penetration: Transport opposed by systemic and antigen-mediated clearance Adv. Drug Delivery Rev. 2008, 60, 1421-1434
49. Lee, H.; Fonge, H.; Hoang, B.; Reilly, R. M.; Allen, C. The Effects of Particle Size and Molecular Targeting on the Intratumoral and Subcellular Distribution of Polymeric Nanoparticles Mol. Pharmaceutics 2010, 7, 1195-1208
50. Jain, R. K.; Stylianopoulos, T. Delivering nanomedicine to solid tumors Nat. Rev. Clin. Oncol. 2010, 7, 653-664
51. Minchinton, A. I.; Tannock, I. F. Drug penetration in solid tumours Nat. Rev. Cancer 2006, 6, 583-592
52. Groos, E.; Walker, L.; Masters, R. W. Intravesical chemotherapy. Studies on the relationship between pH and cytotoxicity Cancer 1986, 58, 1199-1203